The FDA has declared the shortage of tirzepatide, a popular weight-loss drug, resolved. However, semaglutide, another weight-loss medication, remains in short supply. This development raises questions about the long-term viability of compounded GLP-1 treatments, with Hims & Hers Health, a provider of compounded GLP-1s, seeing continued strong demand, but facing investor concerns.